Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing PIKTOR, an investigational all-oral, ...
Experts in cell signaling at the Babraham Institute have identified how prostate cancer cells achieve cell growth free from the usual growth cues and regulators. This discovery has implications for ...
The phosphatidylinositol 3-kinase (PI3K)-AKT signaling pathway is one of the most critical and extensively investigated signaling pathways. It is the central regulator of various cellular processes ...
BLU-222, an investigational, oral, potent, and highly selective CDK2 inhibitor (CDK2i), as monotherapy in patients (pts) with advanced solid tumors and in combination with ribociclib (RIBO) and ...
"Our finding that the PI3K/Akt pathway is anchored on p53 in the nucleus was entirely unexpected," says Cryns, a physician-scientist and professor at UW School of Medicine and Public Health. The ...
WNT pathway alterations in bevacizumab-treated early-onset colorectal cancer: An artificial intelligence–driven and disparity-aware precision oncology analysis. Longitudinal clinical validation of the ...
Morning Overview on MSN
The FDA approved a new pill for an aggressive, hard-to-treat form of advanced breast cancer
Women diagnosed with HR-positive, HER2-negative advanced breast cancer who lack a specific genetic mutation gained a new treatment option on July 14, 2026, when the Food and Drug Administration ...
An investigator behind gedatolisib's FDA approval discusses the trial data, dosing, and adverse effects shaping HR+/HER2- ...
The FDA approved the PI3K-pathway inhibitor inavolisib (Itovebi) for use in combination with palbociclib (Ibrance) and fulvestrant to treat locally advanced, PIK3CA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results